Почетна › Рак на бели дробови со не-мали клетки › Конектикат › New Haven
Клинички испитувања за Рак на бели дробови со не-мали клетки во New Haven, CT
Една студија за Рак на бели дробови со не-мали клетки бара учесници на локација во или блиску до New Haven. Отворете ја за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Се регрутираФаза 2
- Yale New Haven Hospital /ID# 271584, New Haven
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Се регрутираФаза 3
- Yale University, New Haven
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven · на 3 милји
- Yale-New Haven Hospital North Haven Medical Center, North Haven · на 7 милји
- и уште 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Се регрутираФаза 1/2
- Yale Cancer Center, New Haven
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Се регрутираФаза 3
- Yale University School of Medicine ( Site 0201), New Haven
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Се регрутираФаза 1
- Exelixis Clinical Site #62, New Haven
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Се регрутираФаза 3
- Smilow Cancer Center at Yale-New Haven ( Site 3253), New Haven
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Се регрутираФаза 2
- Yale Cancer Center, New Haven
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Се регрутираФаза 1
- Smilow Cancer Hospital - Yale New Haven Health, New Haven
- Yale - New Haven Hospital - Yale Cancer Center, New Haven
- Smilow Cancer Hospital Phase 1 Unit, New Haven
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Се регрутираФаза 1
- Yale Cancer Center, New Haven
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Се регрутираФаза 3
- Yale University, Smillow Cancer Center, New Haven
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Се регрутираФаза 2
- Yale University, New Haven
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Се регрутираФаза 2
- Yale New Haven Hospital Yale Cancer Center, New Haven
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Се регрутираФаза 2
- Research Site, New Haven
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Се регрутираФаза 1
- Yale University, Yale Cancer Center, New Haven
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Се регрутираФаза 3
- Research Site, West Haven · на 3 милји
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Се регрутираФаза 1
- Yale Cancer Center, New Haven
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Се регрутираФаза 1/2
- Yale University School of Medicine - Yale Cancer Center, New Haven
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Се регрутираФаза 1/2
- Yale Cancer Center, New Haven
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Се регрутираФаза 2
- Yale Cancer Center, New Haven
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
Се регрутираФаза 1
- Yale Cancer Center, New Haven
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Се регрутираФаза 1/2
- Yale Cancer Center, New Haven
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Се регрутираФаза 3
- Yale University School of Medicine, New Haven
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Се регрутираФаза 1
- Yale Cancer Center, New Haven
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Се регрутираФаза 1
- Yale Cancer Center, New Haven
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Се регрутираФаза 1/2
- Yale University, New Haven
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Се регрутираФаза 3
- Research Site, New Haven
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Се регрутираФаза 1/2
- Yale University, New Haven
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Се регрутираФаза 1/2
- Yale University - Cancer Center, New Haven
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Се регрутираФаза 1/2
- Yale New Haven Hospital, Yale Cancer Center, New Haven
Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
Се регрутираФаза 1/2
- Smilow Cancer Hospital, New Haven
- Smilow Cancer Hospital - Hamden Care Center, Hamden · на 6 милји
- Smilow Cancer Hospital Care Center - Guilford, Guilford · на 13 милји
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Се регрутираФаза 1
- Yale University School of Medicine /ID# 225707, New Haven
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Се регрутираФаза 2
- Yale University, New Haven
- Smilow Cancer Hospital-Orange Care Center, Orange · на 5 милји
- Yale-New Haven Hospital North Haven Medical Center, North Haven · на 7 милји
- и уште 2
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Се регрутираФаза 1
- Smilow Cancer Hospital (Yale University), New Haven
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Се регрутираФаза 1
- Yale University, New Haven
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Се регрутираФаза 2
- Yale University, New Haven
- Yale-New Haven Hospital North Haven Medical Center, North Haven · на 7 милји
- Smilow Cancer Hospital-Derby Care Center, Derby · на 8 милји
- и уште 1
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Се регрутираФаза 2/3
- Yale University, New Haven
- Yale-New Haven Hospital North Haven Medical Center, North Haven · на 7 милји
- Smilow Cancer Hospital-Derby Care Center, Derby · на 8 милји
- и уште 1
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Се регрутираФаза 2
- Yale University, New Haven
- Yale-New Haven Hospital North Haven Medical Center, North Haven · на 7 милји
- Smilow Cancer Hospital-Derby Care Center, Derby · на 8 милји
- и уште 1
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Се регрутираФаза 2
- Smilow Cancer Hospital at Yale - New Haven, New Haven
- Yale-New Haven Hospital- Yale Cancer Center, New Haven
- Smilow Cancer Hospital Phase 1 Unit, New Haven
- и уште 1
Repositioning Immunotherapy in VetArans With Lung Cancer
Се регрутираФаза 2
- VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven · на 3 милји
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Се регрутираФаза 1/2
- Yale University, New Haven
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Се регрутираФаза 1/2
- Yale Cancer Center, New Haven
Испитувања за Рак на бели дробови со не-мали клетки во други градови
- Houston, TX145 студии
- New York City, NY121 студија
- Arlington, VA104 студии
- Nashville, TN97 студии
- Boston, MA90 студии
- Los Angeles, CA87 студии
- St. Louis, MO73 студии
- Chicago, IL61 студија
- Baltimore, MD60 студии
- San Antonio, TX59 студии
- Columbus, OH57 студии
- Washington, DC55 студии
Други студии во New Haven
- Рак на дојка38 студии
- Рак (сите типови)33 студии
- Метастатски карцином23 студии
- Рак на бели дробови22 студии
- Сквамозноклеточен карцином на глава и врат22 студии
- Карцином на јајниците21 студија
- Колоректален карцином20 студии
- Рак на простата20 студии
- Акутна миелоидна леукемија17 студии
- Растројство во употребата на алкохол (AUD)17 студии
- Предозирање со опиоиди17 студии
- Карцином на панкреасот16 студии
Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.